{"analyses":[{"ciLowerLimit":"0.58","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.94","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0139","paramType":"Hazard Ratio (HR)","paramValue":"0.73","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.0","upperLimit":"5.0","value":"3.3"},{"groupId":"OG001","lowerLimit":"2.8","upperLimit":"3.0","value":"2.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"126"}],"units":"Participants"}],"description":"Progression free survival (PFS) is defined as the time from randomization to the date of progression (RECIST v1.1) or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tebentafusp administered at 20 mcg at Cycle 1 Day 1, 30 mcg at Cycle 1 Day 8, and 68 mcg at Cycle 1 Day 15 by IV infusion and weekly thereafter.","id":"OG000","title":"Tebentafusp"},{"description":"1 of 3 Investigator's Choice options: Systemic Dacarbazine, Ipilimumab or Pembrolizumab. Dacarbazine: administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity; Ipilimumab: administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments; Pembrolizumab: administered at 2 mg/kg IV infusion up to a maximum of 200 mg administered Intravenously over 30 minutes every 3 weeks or 200 mg fixed dose administered intravenously every 3 weeks where approved locally until confirmed disease progression or unacceptable toxicity.","id":"OG001","title":"Investigator's Choice"}],"paramType":"MEDIAN","populationDescription":"The Intent-to-treat (ITT) Analysis Set comprises all participants assigned to treatment analyzed by the treatment assignment whether or not the participant received the assigned treatment. Combining participants into a single group as part of the Investigator's Choice arm was pre-specified as part of the study design; therefore, data per different treatments were not analyzed.","reportingStatus":"POSTED","timeFrame":"PFS was assessed every 3 months from randomization until disease progression or death, up to 36 months.","title":"Efficacy: Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}